Multiple myeloma (published in 2004)

2004-06-01   Franck Viguié 

1.Laboratoire de Cytogenetique - Service dHematologie Biologique, Hopital Hotel-Dieu - 75181 Paris Cedex 04, France
2.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Clinics and Pathology

Disease

multiple myeloma (MM) is a malignant monoclonal plasma cell proliferation. Monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma (SMM) are premalignant states susceptible to transform in MM

Phenotype stem cell origin

phenotype of mature terminally differenciated B-cell, but also with CD56 expression, which is not found in normal plasma cells; CD138+.CD38+ CD40+

Epidemiology

multiple myelomas annual incidence: 30/106; i.e. around 1% of malignancies in adults and 10% of haematologic malignancies; mean age: 62 yrs

Clinics

patients may be asymptomatic at the time of diagnosis; bone pain; susceptibility to infections; renal failure; neurologic dysfunctions

Pathology

MM staging: stage I: tumour cell mass < 0.6 X 1012/m2; Hb> 10 g/dl; serum calcium ¾ 120 mg/l; no bone lesion; low monoclonal Ig rate (IgG < 50 g/l, IgA < 30 g/l, BJ urine < 4 g/day); stage II: fitting neither stage I nor stage II; stage III: tumour cell mass > 1.2 X 1012/m2; Hb< 8.5 g/dl and/or serum calcium > 120 mg/l and/or advanced lytic bone lesions and/or high monoclonal Ig rate (IgG > 70 g/l, IgA > 50 g/l, BJ urine > 12 g/day)

Treatment

none before onset of symptoms; chemotherapy or BMT afterwards. Various new therapies, mainly acting by apoptosis induction in MM cells, are or will be involved in clinical trails (thalidomide, proteasome inhibitor PS-341, 2 methoxy estradiol, arsenic trioxyde, TNF alpha).

Prognosis

evolution: multiple myeloma can evolve towards plasma cell leukemia, where plasma cell count is greater than 2000/ mm3; survival is highly variable (median is around 3 yrs); prognosis is according to the staging and other parameters (such as age, serum albumin, b2 microglobulin, C-reactive protein, and plasma cell labeling index); the karyotype is emerging as an important prognostic factor: median survival in case of a normal karyotype could be 4 yrs vs 1 yr in case of -13/del(13q) and/or 11q rearrangements (the chromosome anomalies with the worst prognostic impact)

Cytogenetics

Cytogenetics morphological

cytogenetic information is limited, as the malignant cells have a low spontaneous proliferative activity; abnormal karyotypes are found in 30-50% of cases, more often in advanced stages than in newly diagnosed patients (is this because chromosome abnormalities are secondary events, or because malignant cells have an increased proliferative activity in advanced stages: see below); karyotypes are complex; hyperploidy is found in 2/3 of cases; karyotypes may evolve from normal to abnormal during course of the disease;
- structural (and variable) anomalies of chromosome 1 are found in 30-40% of cases, 14q rearrangements in 25% of cases, 11q abnormalities in 20 %, t(11;14)(q13;q32) representing 10%; 6q anomalies represent 15% of cases; FISH is indicated, as metaphases are arduous to obtain in such a disease implicating mature cells, and tend to show that most cases bear chromosome anomalies, irrespective of the disease staging.

Cytogenetics molecular

All MM cells should express chromosome abnormalities, as strongly suggested by interphase FISH and CGH.
Aneuploidy is detected in 67-90% of cases, allowing to define 2 prognosis entities:
1) hyperdiploid sub-group with a significantly better overall survival, gains involving primarily +3, +5, +7, +9, +11, +15, +19, +21 and infrequent structural abnormalities.
2) hypodiploid group (+hypotetraploid cases by endoreduplication of a prior hypodiploid karyotype) strongly correlated with complex structural rearrangements, 14q32 translocations, del(13q)/-13 and a more aggressive evolution.
IG rearrangements: translocations involving 14q32 are found in at least 65-70% of patients, most of them result from short segments exchange and are detected quite exclusively by FISH. Five translocations involving IGH locus are particularly relevant and considered as very early primary events: t(4;14)(p16;q32), t(6;14)(p25;q32), t(11;14)(q13;q32), t(14;16)(q32;q23), t(14;20)(q32;q11). Other translocations involving IGH are rare or sporadic, they should be secondary and not mediated by specific recombination mechanisms.
Del13q/-13: 13q14.3 deletions emerge as a major independant pronostic factor, underevaluated by conventional cytogenetics; found by FISH in 20-30% of patients; associated with a significant lower rate of response to conventional chemotherapy, and to a shorter survival.

Genes Involved and Proteins

Gene name
FGFR3 (Fibroblast Growth Factor Receptor 3)
Location
4p16.3
Note
Involved in t(4;14)(p16;q32), approximately 15% of MM cases. FGFR3 (tyrosine kinase receptor) and MMSET (novel gene homologous to a Drosophila dysmorphy gene, see below)) are in opposite transcriptional orientation at 4p16. Both are involved in t(4;14). The translocation generates 2 fusion genes, IGH-MMSET on der(4) and FGFR3-IGH on der(14).
Gene name
Location
4p16
Note
involved in t(4;14)(p16;q32) (see above)
Gene name
CCND3 (cyclin D3)
Location
6p21.1
Note
Involved in t(6;14)(p21;q32) (3-5% of MM cases). Detected quasi exclusively by FISH.
Gene name
CCND1 (B-cell leukemia/lymphoma 1)
Location
11q13.3
Note
BCL1 (also called Cyclin D1 or CCND1) is involved in t(11;14) )(q13;q32) cases. Approximately 15-20% of cases. Same translocation as mantle cell lymphoma but IGH breakpoint different (IGHS vs IGHJ)
Gene name
MAF (v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian))
Location
16q23.2
Note
basic zipper transcription factor, involved in t(14;16)(q32;q23) (5% of MM cases). Detected quasi exclusively by FISH
Gene name
MAFB (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B)
Location
20q12
Note
MAF family basic region / leucine zipper transcription factor, involved in t(14;20)(q32;q11) (2% of MM cases)

Bibliography

Pubmed IDLast YearTitleAuthors
91159681997Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations.Calasanz MJ et al
90812011997Cytogenetics and molecular genetics in multiple myeloma.Feinman R et al
149892512004Genetics and cytogenetics of multiple myeloma: a workshop report.Fonseca R et al
126480632003Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.Harrison CJ et al
150904482004Advances in biology of multiple myeloma: clinical applications.Hideshima T et al
93720081995Multiple myeloma and chronic lymphocytic leukemia.Rosen L et al
115680112001Hypodiploidy is a major prognostic factor in multiple myeloma.Smadja NV et al

Summary

Note

see the more recent paper on Multiple Myeloma

Citation

Franck Viguié

Multiple myeloma (published in 2004)

Atlas Genet Cytogenet Oncol Haematol. 2004-06-01

Online version: http://atlasgeneticsoncology.org/haematological/2038/multiple-myeloma-(published-in-2004)

Historical Card

1998-01-01 Multiple myeloma (published in 2004) by  Jean-Loup Huret 

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

External Links